MarketPulse

CML treatment

3 articles
BenzingaBenzinga··Vandana Singh

Merck Slashes Terns Pharma Offer to $53/Share After Trial Data Disappoints

Merck cut its Terns Pharmaceuticals offer to $53/share from $61 following disappointing TERN-701 trial data, with a competing bidder also withdrawing its offer.
MRKNVSTERNacquisitionclinical trial data
GlobeNewswire Inc.GlobeNewswire Inc.··Ascentage Pharma Group International

Ascentage Pharma's Revenue Surges 90% on Olverembatinib, Lisaftoclax Growth

Ascentage Pharma reports 90% revenue growth to $82.1M in 2025, driven by Olverembatinib and newly launched Lisaftoclax, despite $177.7M net loss.
AAPGbiopharmaceuticalcancer therapy
BenzingaBenzinga··Vandana Singh

Merck's $6.7B Terns Deal Could Attract Rival Bidders as Patent Cliff Looms

Merck agrees to acquire Terns Pharmaceuticals for $6.7B to strengthen pipeline before Keytruda's 2028 patent expiry, but analysts suggest competing bids may emerge.
MRKNVSRVMDRVMDWTERNacquisitionM&A